Horizon Therapeutics Sees Unusually Large Options Volume (NASDAQ:HZNP)

Horizon Therapeutics PLC (NASDAQ:HZNP) saw unusually large options trading on Monday. Stock investors purchased 2,368 put options on the company. This represents an increase of 1,033% compared to the average daily volume of 209 put options.

HZNP opened at $31.93 on Tuesday. The stock has a market capitalization of $6.14 billion, a PE ratio of 17.45, a P/E/G ratio of 1.97 and a beta of 0.87. Horizon Therapeutics has a one year low of $17.94 and a one year high of $33.21. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.23 and a current ratio of 2.33. The business’s 50 day moving average price is $29.83 and its 200 day moving average price is $26.53.

Horizon Therapeutics (NASDAQ:HZNP) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.14. Horizon Therapeutics had a return on equity of 27.71% and a net margin of 5.25%. The company had revenue of $335.50 million for the quarter, compared to the consensus estimate of $330.60 million. During the same quarter in the previous year, the business earned $0.65 earnings per share. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. As a group, equities research analysts forecast that Horizon Therapeutics will post 1.55 earnings per share for the current fiscal year.

In other Horizon Therapeutics news, CEO Timothy P. Walbert sold 320,174 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $28.02, for a total value of $8,971,275.48. Following the transaction, the chief executive officer now directly owns 892,483 shares in the company, valued at $25,007,373.66. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Paul W. Hoelscher sold 20,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $28.01, for a total value of $560,200.00. Following the completion of the sale, the chief financial officer now directly owns 149,310 shares of the company’s stock, valued at $4,182,173.10. The disclosure for this sale can be found here. Insiders have sold 395,956 shares of company stock valued at $11,118,487 over the last 90 days. 4.10% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the stock. Aperio Group LLC increased its stake in Horizon Therapeutics by 1.9% in the second quarter. Aperio Group LLC now owns 36,067 shares of the biopharmaceutical company’s stock valued at $868,000 after purchasing an additional 676 shares during the period. Virginia Retirement Systems ET AL lifted its holdings in shares of Horizon Therapeutics by 1.6% during the second quarter. Virginia Retirement Systems ET AL now owns 65,300 shares of the biopharmaceutical company’s stock worth $1,571,000 after purchasing an additional 1,000 shares during the period. California State Teachers Retirement System lifted its holdings in shares of Horizon Therapeutics by 0.4% during the third quarter. California State Teachers Retirement System now owns 292,915 shares of the biopharmaceutical company’s stock worth $7,976,000 after purchasing an additional 1,095 shares during the period. Bank of Montreal Can grew its position in Horizon Therapeutics by 45.7% in the 2nd quarter. Bank of Montreal Can now owns 3,831 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 1,201 shares during the last quarter. Finally, Regent Investment Management LLC grew its position in Horizon Therapeutics by 0.9% in the 3rd quarter. Regent Investment Management LLC now owns 130,335 shares of the biopharmaceutical company’s stock valued at $3,549,000 after buying an additional 1,225 shares during the last quarter. Hedge funds and other institutional investors own 88.25% of the company’s stock.

Several research firms have commented on HZNP. Zacks Investment Research downgraded shares of Horizon Therapeutics from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. in a report on Tuesday, October 29th. Cantor Fitzgerald raised their price objective on Horizon Therapeutics from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Friday, November 8th. ValuEngine lowered Horizon Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, September 5th. Bank of America assumed coverage on shares of Horizon Therapeutics in a research note on Thursday, September 26th. They set a “buy” rating and a $34.00 price target on the stock. Finally, BidaskClub upgraded shares of Horizon Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 28th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Horizon Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $33.77.

Horizon Therapeutics Company Profile

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Read More: What is the NASDAQ Stock Market?

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply